MXPA04003040A - Uso de inhibidores de calmodulin quinasa ii para tratar la disfuncion miocardica en la enfermedad de corazon estructural. - Google Patents

Uso de inhibidores de calmodulin quinasa ii para tratar la disfuncion miocardica en la enfermedad de corazon estructural.

Info

Publication number
MXPA04003040A
MXPA04003040A MXPA04003040A MXPA04003040A MXPA04003040A MX PA04003040 A MXPA04003040 A MX PA04003040A MX PA04003040 A MXPA04003040 A MX PA04003040A MX PA04003040 A MXPA04003040 A MX PA04003040A MX PA04003040 A MXPA04003040 A MX PA04003040A
Authority
MX
Mexico
Prior art keywords
heart disease
structural heart
inhibitors
myocardial dysfunction
treat myocardial
Prior art date
Application number
MXPA04003040A
Other languages
English (en)
Inventor
Anderson Mark
Original Assignee
Vanderbil University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbil University filed Critical Vanderbil University
Publication of MXPA04003040A publication Critical patent/MXPA04003040A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

La presente invencion proporciona un metodo para tratar la enfermedad de corazon estructural en un sujeto, que comprende administrar una cantidad eficaz de un inhibidor de CaMKII al sujeto, con lo cual la administracion de inhibidor trata la enfermedad de corazon estructural en el sujeto. Tambien se proporcionan modelos de animales transgenicos para tratar la enfermedad de corazon estructural. Ademas se proporcionan medios de deteccion para un compuesto que puede tratar de corazon estructural.
MXPA04003040A 2001-10-01 2002-10-01 Uso de inhibidores de calmodulin quinasa ii para tratar la disfuncion miocardica en la enfermedad de corazon estructural. MXPA04003040A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32657601P 2001-10-01 2001-10-01
US32801001P 2001-10-08 2001-10-08
PCT/US2002/031496 WO2003029428A2 (en) 2001-10-01 2002-10-01 Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease

Publications (1)

Publication Number Publication Date
MXPA04003040A true MXPA04003040A (es) 2004-07-15

Family

ID=26985461

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003040A MXPA04003040A (es) 2001-10-01 2002-10-01 Uso de inhibidores de calmodulin quinasa ii para tratar la disfuncion miocardica en la enfermedad de corazon estructural.

Country Status (14)

Country Link
US (2) US7320959B2 (es)
EP (1) EP1439849A4 (es)
JP (1) JP2005504829A (es)
KR (1) KR20040045041A (es)
CN (1) CN1599622A (es)
AU (1) AU2002341938B2 (es)
BR (1) BR0213043A (es)
CA (1) CA2462443A1 (es)
IL (1) IL161231A0 (es)
MX (1) MXPA04003040A (es)
NO (1) NO20041331L (es)
NZ (1) NZ532327A (es)
PL (1) PL369104A1 (es)
WO (1) WO2003029428A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006049215A1 (ja) * 2004-11-02 2008-05-29 大日本住友製薬株式会社 自己免疫疾患を治療するための併用薬
US20110111526A1 (en) * 2008-04-09 2011-05-12 B.R.A.H.M.S Gmbh Pro-endothelin-1 for the prediction of impaired peak oxygen consumption
US8841423B2 (en) 2008-04-28 2014-09-23 University Of Iowa Research Foundation Monoclonal antibodies specific for oxidized calcium/calmodulin dependent protein kinase II
US20090275514A1 (en) * 2008-05-01 2009-11-05 Anderson Mark E Use of calmodulin kinase ii inhibitors to treat or prevent heart muscle inflammation
US9506032B2 (en) * 2009-05-22 2016-11-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered biological pacemakers
US8440656B2 (en) * 2009-06-22 2013-05-14 University Of Iowa Research Foundation Methods of treating pulmonary diseases and disorders by modulating calcium/calmodulin dependent protein kinase II activity
JP2013506696A (ja) 2009-10-05 2013-02-28 コーネル ユニヴァーシティー 心不全の予防又は処置の方法
CA2901155C (en) 2013-03-06 2021-06-08 Allosteros Therapeutics, Inc. Camkii inhibitors and uses thereof
DE102014201651A1 (de) * 2014-01-30 2015-07-30 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Isoxazolderivate zur Verwendung bei der Behandlung und/oder Prophylaxe von Herzerkrankungen
AU2015311730A1 (en) 2014-09-05 2017-04-20 Allosteros Therapeutics, Inc Camkii inhibitors and uses thereof
WO2018031771A1 (en) 2016-08-11 2018-02-15 University Of Iowa Research Foundation CATIONIC CaMKII INHIBITING NANOPARTICLES FOR THE TREATMENT OF ALLERGIC ASTHMA
CN112972447B (zh) * 2021-03-02 2022-09-23 扬州大学附属医院 CaMK II抑制剂在制备预防和/或治疗急性胰腺炎的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (es) * 1968-10-17 1970-08-24
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
JP2001509808A (ja) * 1997-01-31 2001-07-24 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 多機能性カルシウム／カルモジュリン−依存性プロテインキナーゼの阻害による不整脈の処置
JP2963986B2 (ja) * 1997-11-19 1999-10-18 工業技術院長 カルモジュリン依存性リン酸化酵素ｉｉの特異的阻害剤

Also Published As

Publication number Publication date
IL161231A0 (en) 2004-09-27
WO2003029428A3 (en) 2003-10-30
US20040266675A1 (en) 2004-12-30
NZ532327A (en) 2005-10-28
WO2003029428A8 (en) 2004-04-22
NO20041331D0 (no) 2004-03-31
CN1599622A (zh) 2005-03-23
US7320959B2 (en) 2008-01-22
NO20041331L (no) 2004-05-28
AU2002341938B2 (en) 2007-08-30
BR0213043A (pt) 2004-10-05
PL369104A1 (en) 2005-04-18
KR20040045041A (ko) 2004-05-31
EP1439849A2 (en) 2004-07-28
CA2462443A1 (en) 2003-04-10
WO2003029428A2 (en) 2003-04-10
JP2005504829A (ja) 2005-02-17
US20090011989A1 (en) 2009-01-08
EP1439849A4 (en) 2005-09-28
US7632815B2 (en) 2009-12-15

Similar Documents

Publication Publication Date Title
ATE372341T1 (de) Inhibitoren von mitotischem kinesin
ATE356804T1 (de) Inhibitoren von mitotischem kinesin
ATE424388T1 (de) Mitotische kinesinhemmer
ATE447577T1 (de) Mitotische kinesin-hemmer
MXPA04003040A (es) Uso de inhibidores de calmodulin quinasa ii para tratar la disfuncion miocardica en la enfermedad de corazon estructural.
ATE448207T1 (de) Mitotische kinesin-hemmer
MX342777B (es) Inhibidores tnfa para usarse en el tratamiento de trastornos relacionados con tnfa.
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
BR0108977A (pt) Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina
BR0317183A (pt) Método de usar compostos de aminocianopiridina como inibidores de proteìna quinase-2 ativada por proteìna quinase ativada por mitógeno
DE60318177D1 (de) Rho-kinase inhibitoren
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
ATE446094T1 (de) Mitotische kinesin-hemmer
ATE421512T1 (de) Inhibitoren von mitotischem kinesin
ATE339957T1 (de) Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs
ATE424208T1 (de) Proteinkinaseinhibitoren
MY125490A (en) Method of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
GB9903403D0 (en) Substituted stilbene compounds with vascular damaging activity
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
HUP0301276A2 (hu) Kombinációs terápia ösztrogénérzékeny betegségek kezelésére
ATE516038T1 (de) Metallcluster-nanoverbindungen zur behandlung von tumorerkrankungen
ATE438859T1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
DE60310975D1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus
MX2007002532A (es) Metodos para el tratamiento de enfermedades proliferativas de la piel utilizando derivados de carbazol.
DE60236894D1 (de) Behandlung von statin-nebenwirkungen mit uridinderivaten

Legal Events

Date Code Title Description
FA Abandonment or withdrawal